It is provided an achiral, non-nucleosidic backbone for phosphoramidites that can be inserted with high yields in nucleic acid strands and sequence-controlled oligo(phosphodiester)s through solid phase synthesis (SPS) using a DNA synthesizer. From this backbone, platforms with useful chemical handles were synthesized, further functionalized, transformed into phosphoramidites and attached to nucleic acid strands and sequence-controlled oligo(phosphodiester)s. The backbone is based on a tertiary amine with a 3-6 carbon spacer between the central nitrogen and the two external hydroxyls. The spacer has been optimized to increase coupling yields and stability.

A novel method for synthesizing deuterated amides and deuterated sulfonamides includes the following steps: (1) adding a compound M, DMAP, R.sup.3—X to a solvent to obtain a compound N after a reaction is complete; and (2) adding the compound N, R.sup.4—NH—R.sup.5, or a salt and base thereof to a solvent, and purifying after a reaction is complete to obtain a compound I.

##STR00001##

A novel method for synthesizing deuterated amides and deuterated sulfonamides includes the following steps: (1) adding a compound M, DMAP, R.sup.3—X to a solvent to obtain a compound N after a reaction is complete; and (2) adding the compound N, R.sup.4—NH—R.sup.5, or a salt and base thereof to a solvent, and purifying after a reaction is complete to obtain a compound I.

##STR00001##

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

A compound represented by the following formula (1), wherein X.sub.1 is O or S, and two or more of Y.sub.1, Y.sub.2 and Y.sub.3 are N, provided that the case where one or both of Ar.sub.1Ar.sub.2 and Ar.sub.3Ar.sub.4 is a p-terphenyl-3-yl group is excluded.

##STR00001##

A compound represented by the following formula (1), wherein X.sub.1 is O or S, and two or more of Y.sub.1, Y.sub.2 and Y.sub.3 are N, provided that the case where one or both of Ar.sub.1Ar.sub.2 and Ar.sub.3Ar.sub.4 is a p-terphenyl-3-yl group is excluded.

##STR00001##

The invention relates to a process for preparing triaryl organo borates proceeding from organoboronic esters in the presence of an n-valent cation 1/n K.sup.n+, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms.

The invention relates to a process for preparing triaryl organo borates proceeding from organoboronic esters in the presence of an n-valent cation 1/n K.sup.n+, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms.

An organic electroluminescence device, comprising: an anode, an emitting layer, a first electron-transporting layer, a second electron-transporting layer and a cathode in this order, wherein the second electron-transporting layer comprises a compound represented by the following formula (1), and the emitting layer comprises a compound represented by the following formula (10).

##STR00001##